article thumbnail

Nonclinical Pulmonary Drug Delivery: Setting Up Your Inhalation Drug Study for Success

Camargo

Most are familiar with, know someone who uses, or take “pumps” themselves to prevent or relieve shortness of breath after an effort or during allergy season. Interest in the pulmonary route has also grown in recent years because delivering the drugs through the lungs allows direct systemic delivery and bypasses the first pass metabolism.

article thumbnail

Contact lenses poised to detect cancer, treat disease and replace digital screens

Scienmag

Newly-published “contact lens technologies of the future” paper reviews innovative uses for disease detection and therapy, drug delivery, vision enhancement and mor Credit: Centre for Ocular Research & Education (CORE) WATERLOO, Ontario, March 29, 2021–A newly-published paper represents one of the most comprehensive reviews of (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Roots Analysis

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

article thumbnail

CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine

The Pharma Data

NYU Grossman School of Medicine, Department of Biochemistry and Molecular Pharmacology, who was a principal investigator in the study, which was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institute of Health (NIH). Band, Ph.D.,